🎉 M&A multiples are live!
Check it out!

Catalyst Pharmaceuticals Valuation Multiples

Discover revenue and EBITDA valuation multiples for Catalyst Pharmaceuticals and similar public comparables like Pharming, Galapagos, and Vivoryon Therapeutics.

Catalyst Pharmaceuticals Overview

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).


Founded

2006

HQ

United States of America
Employees

181

Financials

LTM Revenue $508M

LTM EBITDA n/a

EV

$2.3B

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Catalyst Pharmaceuticals Financials

Catalyst Pharmaceuticals has a last 12-month revenue of $508M and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Catalyst Pharmaceuticals achieved revenue of $492M and an EBITDA of $233M.

Catalyst Pharmaceuticals expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Catalyst Pharmaceuticals valuation multiples based on analyst estimates

Catalyst Pharmaceuticals P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $398M $492M XXX XXX XXX
Gross Profit $180M $346M XXX XXX XXX
Gross Margin 45% 70% XXX XXX XXX
EBITDA $120M $233M XXX XXX XXX
EBITDA Margin 30% 47% XXX XXX XXX
Net Profit $83.1M $71.4M XXX XXX XXX
Net Margin 21% 15% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Catalyst Pharmaceuticals Stock Performance

As of April 15, 2025, Catalyst Pharmaceuticals's stock price is $23.

Catalyst Pharmaceuticals has current market cap of $2.8B, and EV of $2.3B.

See Catalyst Pharmaceuticals trading valuation data

Catalyst Pharmaceuticals Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$2.3B $2.8B XXX XXX XXX XXX $1.34

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Catalyst Pharmaceuticals Valuation Multiples

As of April 15, 2025, Catalyst Pharmaceuticals has market cap of $2.8B and EV of $2.3B.

Catalyst Pharmaceuticals's trades at 4.5x LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Catalyst Pharmaceuticals's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Catalyst Pharmaceuticals and 10K+ public comps

Catalyst Pharmaceuticals Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $2.3B XXX XXX XXX
EV/Revenue 4.6x XXX XXX XXX
EV/EBITDA 9.7x XXX XXX XXX
P/E 17.0x XXX XXX XXX
P/E/Growth 1.2x XXX XXX XXX
EV/FCF 9.5x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Catalyst Pharmaceuticals Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Catalyst Pharmaceuticals Valuation Multiples

Catalyst Pharmaceuticals's NTM/LTM revenue growth is 12%

Catalyst Pharmaceuticals's revenue per employee for the last fiscal year averaged $2.7M, while opex per employee averaged $1.3M for the same period.

Over next 12 months, Catalyst Pharmaceuticals's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Catalyst Pharmaceuticals's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Catalyst Pharmaceuticals and other 10K+ public comps

Catalyst Pharmaceuticals Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 23% XXX XXX XXX XXX
EBITDA Margin 47% XXX XXX XXX XXX
EBITDA Growth 95% XXX XXX XXX XXX
Rule of 40 (SaaS-only) 60% XXX XXX XXX XXX
Revenue per Employee $2.7M XXX XXX XXX XXX
Opex per Employee $1.3M XXX XXX XXX XXX
S&M Expenses to Revenue 23% XXX XXX XXX XXX
G&A Expenses to Revenue 14% XXX XXX XXX XXX
R&D Expenses to Revenue 3% XXX XXX XXX XXX
Opex to Revenue 46% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Catalyst Pharmaceuticals Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Catalyst Pharmaceuticals M&A and Investment Activity

Catalyst Pharmaceuticals acquired  XXX companies to date.

Last acquisition by Catalyst Pharmaceuticals was  XXXXXXXX, XXXXX XXXXX XXXXXX . Catalyst Pharmaceuticals acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Catalyst Pharmaceuticals

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Catalyst Pharmaceuticals

When was Catalyst Pharmaceuticals founded? Catalyst Pharmaceuticals was founded in 2006.
Where is Catalyst Pharmaceuticals headquartered? Catalyst Pharmaceuticals is headquartered in United States of America.
How many employees does Catalyst Pharmaceuticals have? As of today, Catalyst Pharmaceuticals has 181 employees.
Who is the CEO of Catalyst Pharmaceuticals? Catalyst Pharmaceuticals's CEO is Mr. Richard J. Daly.
Is Catalyst Pharmaceuticals publicy listed? Yes, Catalyst Pharmaceuticals is a public company listed on NAS.
What is the stock symbol of Catalyst Pharmaceuticals? Catalyst Pharmaceuticals trades under CPRX ticker.
When did Catalyst Pharmaceuticals go public? Catalyst Pharmaceuticals went public in 2006.
Who are competitors of Catalyst Pharmaceuticals? Similar companies to Catalyst Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Catalyst Pharmaceuticals? Catalyst Pharmaceuticals's current market cap is $2.8B
What is the current revenue of Catalyst Pharmaceuticals? Catalyst Pharmaceuticals's last 12-month revenue is $508M.
What is the current EV/Revenue multiple of Catalyst Pharmaceuticals? Current revenue multiple of Catalyst Pharmaceuticals is 4.5x.
What is the current revenue growth of Catalyst Pharmaceuticals? Catalyst Pharmaceuticals revenue growth between 2023 and 2024 was 23%.
Is Catalyst Pharmaceuticals profitable? Yes, Catalyst Pharmaceuticals is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.